Compare AMTD & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTD | ANVS |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 69.1M |
| IPO Year | 2019 | 2019 |
| Metric | AMTD | ANVS |
|---|---|---|
| Price | $0.98 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 13.6K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $1.54 |
| 52 Week High | $1.65 | $5.50 |
| Indicator | AMTD | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.56 | 43.64 |
| Support Level | $0.96 | $1.79 |
| Resistance Level | $1.07 | $2.57 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 13.64 | 24.29 |
AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.